Introduction
The Abbott TDx therapeutic drug-monitoring system is based on fluorescence polarization. Polarization fluoroimmunoassay makes use of competitive binding, measuring the tracer binding directly, without the need for separation procedures. The attraction of non-radioactive polarization fluoroimmunoassay for the determination of T-uptake is that there is no radiation hazard and that the homogeneous method is very convenient. 
Results and discussion Replication experiment
Three replication experiments---'mini', 'midi', and 'maxi'--are described by the National Committee for Clinical Laboratory Standards (NCCLS) in the proposed standard [1] and these were consulted for the evaluation. The experimental design permits estimation of within-run, between-run within a day, between-run between days, and total variance. The midi and maxi experiments permit calculation of the variance excluding and including carry-over effects. The TDx therapeutic drug monitoring system measures by fluorescence polarization im- munoassay. An estimation of the effects of carry-over with the TDx was considered important--it is a discrete system and the probe may contribute to carry-over. Abbott Laboratories, in their Operator's Manual [2] , claim that carry-over is less than 1.5%. The midi experiment is an efficient method where three different levels control materials need to be analysed for Tuptake six times per analytical run, with two runs per day for 20 working days. This gave a total of 240 observations at each level. 
